Is ARQT or TARS more profitable?

ARQT runs the higher net margin — ARQT at 6.15% versus TARS at -7.67%.

How have ARQT and TARS total returns compared?

Over the past 5 years, ARQT delivered -0.28% and TARS delivered 28.33% annualized total return. Past performance doesn't predict future results.

Arcutis Biotherapeutics, Inc. (ARQT) vs Tarsus Pharmaceuticals, Inc. (TARS)

A side-by-side comparison of Arcutis Biotherapeutics, Inc. and Tarsus Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ARQT

Arcutis Biotherapeutics, Inc.

$2.99B

$23.92HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

TARS

Tarsus Pharmaceuticals, Inc.

$3.20B

$74.27HealthcareDelayed quote: Oct 6, 2026, 3:55 PM EDT

Total return — ARQT vs TARS

growth of $100 · dividends reinvested · last 6y

ARQT +4.8% (+0.8%/yr)TARS +261.8% (+23.9%/yr)TARS compounded faster over this window

ARQT TARS

ARQT vs TARS: by the numbers

•TARS is the larger company ($3.20B vs $2.99B market cap).
•ARQT is profitable (6.15% net margin) while TARS runs a net loss (-7.67%).

Metrics side by side

Valuation

Metric	ARQT	TARS
P/E ratio	114.72	N/A
Forward P/E	48.12	N/A
P/S ratio	6.45	5.27
P/B ratio	13.56	9.22
EV / EBITDA	82.57	N/A
FCF yield	1.31%	1.93%

Profitability

Metric	ARQT	TARS
Gross margin	91.14%	90.59%
Operating margin	-3.25%	-8.00%
Net margin	6.15%	-7.67%
ROE	12.93%	-13.40%
ROIC	9.95%	-11.15%

Growth (annualized)

Metric	ARQT	TARS
Revenue CAGR (5Y)	N/A	61.36%
Total return CAGR (5Y)	-0.28%	28.33%

Frequently asked

Is ARQT or TARS more profitable?: ARQT runs the higher net margin — ARQT at 6.15% versus TARS at -7.67%.
How have ARQT and TARS total returns compared?: Over the past 5 years, ARQT delivered -0.28% and TARS delivered 28.33% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ARQT analysis Full TARS analysis Interactive comparison tool

Dig into the metrics

Arcutis Biotherapeutics P/E ratio Arcutis Biotherapeutics ROE Tarsus Pharmaceuticals ROE Arcutis Biotherapeutics operating margin Tarsus Pharmaceuticals operating margin Arcutis Biotherapeutics revenue growth Tarsus Pharmaceuticals revenue growth Arcutis Biotherapeutics free cash flow Tarsus Pharmaceuticals free cash flow

Arcutis Biotherapeutics & Tarsus Pharmaceuticals appear in these rankings

Fastest Revenue Growth Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.